Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis-Reference-Cited by-同舟云学术

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Published:2017-08 Issue:2 Volume:67 Page:263-271
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Kwo Paul Y.,Poordad Fred,Asatryan Armen,Wang Stanley,Wyles David L.,Hassanein Tarek,Felizarta Franco,Sulkowski Mark S.,Gane Edward,Maliakkal Benedict,Overcash J. Scott,Gordon Stuart C.,Muir Andrew J.,Aguilar Humberto,Agarwal Kosh,Dore Gregory J.,Lin Chih-Wei,Liu Ran,Lovell Sandra S.,Ng Teresa I.,Kort Jens,Mensa Federico J.

Publisher

Elsevier BV

Subject

Hepatology

Reference22 articles.

1. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm;Razavi;J Viral Hepatitis,2014

2. Global distribution and prevalence of hepatitis C virus genotypes;Messina;Hepatology,2015

3. Global epidemiology and genotype distribution of the hepatitis C virus infection;Gower;J Hepatol,2014

4. Review article: HCV genotype 3 - the new treatment challenge;Ampuero;Aliment Pharmacol Ther,2014

5. EPCLUSA (sofosbuvir and velpatasvir) [package insert];Sciences,2016

Cited by 266 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Data on the Use of Glecaprevir/Pibrentasvir in the Treatment of Hepatitis C: Is Shorter Treatment Possible?;Viral Hepatitis Journal;2024-08-28

2. A COMPARISON OF SOFOSBUVIR/VELPATASVIR (S/V) AND GLECAPREVIR/PIBRENTASVIR (G/P) FOR THE TREATMENT OF HCV INFECTION AMONG HCV-INFECTED PEOPLE WHO USE DRUGS (PWUD);Journal of Virus Eradication;2024-08

3. Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors;Scientific Reports;2024-07-16

4. Genetic diversity of hepatitis C virus and the prevalence of resistance mutations to NS5A inhibitors in the Krasnoyarsk region;South of Russia: ecology, development;2024-04-07

5. Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C: A nationwide, prospective, multicenter study;JGH Open;2024-04